Precision medicine
MR Kosorok, EB Laber - Annual review of statistics and its …, 2019 - annualreviews.org
Precision medicine seeks to maximize the quality of health care by individualizing the health-
care process to the uniquely evolving health status of each patient. This endeavor spans a …
care process to the uniquely evolving health status of each patient. This endeavor spans a …
Non-hodgkin lymphoma
JO Armitage, RD Gascoyne, MA Lunning, F Cavalli - The lancet, 2017 - thelancet.com
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …
be seen by primary care physicians and physicians from most specialties. They are …
ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma
GS Nowakowski, A Chiappella… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …
Genetic and functional drivers of diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a …
B Coiffier, C Thieblemont… - Blood, The Journal …, 2010 - ashpublications.org
We report the outcome of patients included in the LNH-98.5 study, which compared
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus …
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus …
Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European …
NS Agar, E Wedgeworth, S Crichton… - Journal of clinical …, 2010 - ascopubs.org
Purpose We have analyzed the outcome of mycosis fungoides (MF) and Sézary syndrome
(SS) patients using the recent International Society for Cutaneous Lymphomas …
(SS) patients using the recent International Society for Cutaneous Lymphomas …
Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their …
J Ding, JE Karp, A Emadi - Cancer Biomarkers, 2017 - content.iospress.com
Metabolism of neoplastic cells is shifted toward high glucose uptake and enhanced lactate
production. Lactate dehydrogenase (LDH), which is comprised of two major subunits, LDH-A …
production. Lactate dehydrogenase (LDH), which is comprised of two major subunits, LDH-A …
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
X Bi, H Wang, W Zhang, J Wang, W Liu, Z Xia… - Journal of hematology & …, 2016 - Springer
Background Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-
associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal …
associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal …
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni, AWA Lensing, A Piccioli… - Blood, The Journal …, 2002 - ashpublications.org
A small proportion of patients with deep vein thrombosis develop recurrent venous
thromboembolic complications or bleeding during anticoagulant treatment. These …
thromboembolic complications or bleeding during anticoagulant treatment. These …